A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk

Name: A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
License: Public Domain

Tianjin Medical University Cancer Institute and Hospital · clinicaltrials

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

hcc - hepatocellular carcinoma, iparomlimab and tuvonralimab injection, neoadjuvant immunotherapy

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Record · ID 121342 · SHA-256 e5bfa50054351e7a
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.